INTRODUCTION
Over the last 25 years a series of multicentre studies by the Medical Research Council has shown a progressive improvement in the survival of patients with multiple myeloma.1 -4 This has been achieved through an increase in the intensity of chemotherapeutic regimens and an improvement in supportive care. The outcome of any trial will be affected by the preselection of patients for the trial and may often lead to apparently significant improvement in progress. 5 The present study describes the outcome for an unselected group of patients diagnosed and treated at this hospital during a five year period with follow -up to death, or for one to five years survival. In 1990, the most recent year for which accurate figures are available, 92 patients were diagnosed as having multiple myeloma in Northern Ireland. (Northern Ireland Leukaemia Research Fund data collection service).
The Ulster Medical Journal METHODS Sixty -nine patients with multiple myeloma diagnosed in the Belfast City Hospital between 1 January 1986 and 31 December 1990 were identified using the records of bone marrow examination and protein biochemistry. Administration of chemotherapy was supervised by the staff of the haematology department. The clinical haematology charts of all the patients were analysed to determine outcome. Laboratory findings utilised for diagnosis of myeloma included plasma cell infiltration in the bone marrow greater than 5 %, a paraprotein band in serum or urine, and lytic bone lesions on skeletal radiography. Patients were staged according to the Durie- one category compared to a reference category; for continuous variables the change in risk associated with a one unit change in the variable is expressed.
PATIENTS AND TREATMENT Two of the 69 patients were excluded from follow -up analysis as they moved away from the Belfast area. Of the remaining 67, 31 were male (46%) and 36 female (54%). Median age at diagnosis was 66 years for males (range 39-84 years) and 67-5 years for females (range 44-83 years). Twenty-eight patients (42 %) were alive at the end of the study. The types of paraprotein were as shown in Table 11 . Even though overall survival in myeloma may not have improved dramatically since the introduction of melphalan, much can now be done to palliate this devastating illness. The majority of patients have good quality survival and most are managed as outpatients. Recent developments such as the use of interferon to prolong plateau phase and the use of G -CSF to harvest peripheral blood stem cells and increase the safety of marrow transplantation suggest that further improvement in survival may now be obtainable.
